0000000000365901
AUTHOR
Florence Thomas
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study
BACKGROUND: The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is immunogenic, has a clinically acceptable safety profile, and prevents incident and persistent HPV-16/18 infection and cervical precancerous lesions. This study (NCT00552279) evaluated the vaccine when administered according to an alternative dosing schedule (0-1-12 months) compared with the standard dosing schedule (0-1-6 months). METHODS: The study was of randomized open design and was conducted at multiple centers in Europe. Healthy women aged 15 to 25 years were randomized (1:1) to receive HPV-16/18 vaccine according to the standard schedule at months 0, 1, and 6 (n = 401) or an alternative schedule at months 0, …
276 Evaluation of cardiovascular risk and factors associated to risk under-evaluation in general practice
Correlation between perceived cardiovascular risk (CVR) by physicians and real CVR is poorly known. Moreover, the underlying question of factors associated to risk misevaluation, especially for patients at high CVR and that could benefit of a lipid lowering therapy (LLT), remains unsolved. Objective and methodology This was an on-line non-interventional study conducted on a sample of 619 general practitioners. The aim was to describe the relation between physicians evaluated CVR and calculated CVR according to risk's scales. All consulting patients’ aged50 years old (YO) were included. Physicians had to complete a questionnaire and to assess patient's CVR on a 3 level scale (low, medium, an…